-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Raises Price Target to $17

Benzinga·03/16/2026 16:11:25
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises the price target from $10 to $17.